Determination of Biological Age: Geriatric Assessment vs Biological Biomarkers
Grading of frailty is a demonstrably, clinically, and research-relevant proxy estimate of biological age, and biomarkers can supplement this approach by identifying accelerated aging before it is clinically apparent.
Abstract
The degree of frailty predicts susceptibility to adverse outcomes independently of chronological age. The utility of this approach has been demonstrated across a range of clinical contexts. Biomarkers from various levels of the biological aging process are improving in accuracy, with the potential to identify aberrant aging trajectories before the onset of clinically manifest frailty. Grading of frailty is a demonstrably, clinically, and research-relevant proxy estimate of biological age. Emerging biomarkers can supplement this approach by identifying accelerated aging before it is clinically apparent. Some biomarkers may even offer a means by which interventions to reduce the rate of aging can be developed.